biote (BTMD)
Builds and supports clinician practices offering pellet-based hormone optimization.
Something off on this page? Send us feedback.
Supplies certified practitioners with education, training, certification and platform support for pellet-based hormone optimization. It operates through a practice-building model while practitioners, rather than the company, provide care to patients.
Provides education, training, certification and other platform support for clinicians offering pellet-based hormone optimization through the Biote Method. Its practice-building model gives certified practitioners the components to establish a hormone-optimization offering.
The company compares that model to a franchise model. Practitioners provide care to their patients, while biote supports the offering rather than operating the patient clinics itself.
Headquartered in Irving, Texas, biote developed provider-training programs and relationships with outsourcing facilities that compound bioidentical hormone pellets. Its role centers on standardizing clinician training and support around the proprietary Biote Method.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 16, 2026 | Truist Financial | Target | Target: $5 | Target: $4 |
| Mar 12, 2026 | National Bank | Target | Target: — | Target: $2.50 |
| Jan 7, 2026 | Truist Financial | Target | Target: $9 | Target: $5 |
| Aug 7, 2025 | B. Riley Securities | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.2M · Total debt $128.6M · Total assets $101.7M · Shareholders' equity −$65.8M
- Revenue
- $44.2M
- Operating income
- −$3.5M
- Net income
- −$6.6M
No dividends on record.
| Institutions | 35.04% | 13.17M shares | |
|---|---|---|---|
| 73 holders · as of Jun 30, 2026 | |||
| Insiders | 15.81% | 5.94M shares | |
| 7 holders · as of Sep 18, 2026 | |||
| Other | 49.15% | 18.47M shares | |
| remainder | |||
37.58M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (37.58M in the company's Sep 22, 2026 report, 44.11M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
325 Capital LLCInstitution | 12.10% | 4.55M A | as of Jun 30, 2026 |
Marc D. BeerInsiderdirector, officer: Executive Chairman | 8.53% | 239,744 A · 2.97M V | filed Aug 12, 2026 |
Agarwal Amit MohanInsider | 6.39% | 2.40M | filed Sep 18, 2026 |
Bandera Partners LLCInstitution | 5.50% | 2.07M A | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.93% | 1.10M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 11, 2026 | Marc D. Beer | director, officer: Executive Chairman | +16,000 | $1.55 |
| Aug 10, 2026 | Marc D. Beer | director, officer: Executive Chairman | +115,950 | $1.53 |
- Hims & Hers Health
Direct-to-consumer menopause care with estradiol and progesterone
- LifeMD
Direct-to-consumer telehealth path for EstroGel hormone therapy
- Pfizer
FDA-approved oral menopause therapy with conjugated estrogens
- Viatris
Transdermal and local estradiol alternatives for hormone care
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| biote | $1.33 | +0.38% | $58.4M | 11.4 | 13.9 | 0.3 | −9.5% |
| Hims & Hers Health | $30.69 | +4.57% | $6.55B | — | 142.7 | 2.5 | +38.3% |
| LifeMD | $3.35 | +3.72% | $156.0M | — | — | 0.8 | −24.0% |
| Pfizer | $27.97 | +0.83% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Viatris | $17.16 | +0.32% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Median | 36.7 | 10.0 | 1.9 | +3.7% |